About
Peptide Drugs
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyMidwest
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
6
As Collaborator
2
Total Enrollment
244
By Phase
PHASE3: 2PHASE1/PHASE2: 3NA: 2PHASE1: 1
By Status
COMPLETED: 6WITHDRAWN: 2
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
Today
Hover over trial bars to see details
Recent Trials
NCT01804829Lead Sponsor
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
PHASE3Completed
80 participants
Started: Jun 30, 2013 · Completed: Jun 30, 2016
NCT01638936Lead Sponsor
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
PHASE1/PHASE2Completed
64 participants
Started: Jul 3, 2012 · Completed: Oct 30, 2018
NCT01001442Lead Sponsor
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
PHASE1/PHASE2Completed
35 participants
Started: Aug 31, 2010 · Completed: Mar 31, 2016
NCT00800787Lead Sponsor
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
PHASE3Withdrawn
Started: Apr 30, 2010 · Completed: Sep 30, 2010
NCT01051076Collaborator
Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
NACompleted
3 participants
Started: Nov 3, 2009 · Completed: Oct 21, 2020
Locations (1)
Headquarters
Columbus, OH, United States
Map
Loading map...